Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06741085 · ClinicalTrials.gov registry record · Phase 2
A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain
A Phase 2 study of Non Small Cell Lung Cancer Metastatic, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 8
- Study locations
NCT06741085: Recruiting Phase 2 study of Non Small Cell Lung Cancer Metastatic, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06741085 is a Phase 2 study of Non Small Cell Lung Cancer Metastatic that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 56 participants, below the 433-participant average among 16 other Non Small Cell Lung Cancer Metastatic trials with a reported enrollment target (87% lower). The trial reports 8 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06741085, a Phase 2 study of Non Small Cell Lung Cancer Metastatic, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 8
- Study locations
Study Summary
The researchers are doing this study is to find out whether treating brain metastasis with SRS after 3 months of therapy with osimertinib is better than treating with osimertinib alone in people with NSCLC. The researchers will also look at how the study intervention impacts participants' quality of life. The researchers will measure quality of life by having participants complete questionnaires.
Primary Outcome
Intracranial progression will be assessed at 3-month intervals and is defined as a ≥20% increase in sum longest distance relative to nadir for target lesions (up to a max of 5 lesions; must include at least one lesion increased in size by an absolute value of 5mm), unequivocal progression of non-target lesions, and/or the presence of new lesions, as defined by the RANO-BM working group criteria
Conditions Studied
Interventions
- DRUG osimertinib
- RADIATION stereotactic radiosurgery (SRS)
Study Locations (8)
New York
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) - Rockville Centre
New Jersey
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
Florida
- BAPTIST ALLIANCE - MCI (Data Collection Only) - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2024-12-13 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT06741085 shows while recruiting
NCT06741085 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 433-participant average among 16 other Non Small Cell Lung Cancer Metastatic trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Non Small Cell Lung Cancer Metastatic appearing as the primary indexed condition, and to 2 interventions - of which osimertinib is the first listed.
NCT06741085 lists 8 locations in 3 states (New York, New Jersey, Florida).
Frequently Asked Questions
What is clinical trial NCT06741085 about?
NCT06741085 is a clinical study titled "A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain". The researchers are doing this study is to find out whether treating brain metastasis with SRS after 3 months of therapy with osimertinib is better than treating with osimertinib alone in people with NSCLC. The researchers will also look at how the study intervention impacts participants' quality of...
What is the current status of trial NCT06741085?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2024-12-13. Estimated completion is 2027-12.
What conditions does trial NCT06741085 study?
This clinical trial studies the following conditions: Non Small Cell Lung Cancer Metastatic.
What interventions are being tested in trial NCT06741085?
The interventions under investigation include: osimertinib (DRUG), stereotactic radiosurgery (SRS) (RADIATION).
Who is sponsoring clinical trial NCT06741085?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06741085 being conducted?
This trial has 8 study locations across Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non Small Cell Lung Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06741085's enrollment target sits among peer trials
56 14th of 16 higher than 2 of 16 other Non Small Cell Lung Cancer Metastatic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non Small Cell Lung Cancer Metastatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
ACTIVE NOT RECRUITING · Phase 2
-
Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI